CpGs positions within close proximity to RUNX1/CEBPA binding sites (TFBS) showed an increase in DNA methylation in AML patients with corresponding mutations in comparison to patients without mutations (Figure 1A,B,D,E,G,H). This evidence concerns the gene CEBPA and acute myeloid leukemia.